AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36705941 — intervention group
Group type: COMPARATOR
Intervention: AMX0035 (a sachet containing a fixed co-formulation of 3 g of PB and 1 g of TURSO given twice daily).
Number of subjects: 0
Study 36705941 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo) in the CENTAUR trial.
Number of subjects: 0
Study 36705951 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel digital digit-symbol substitution test (DDSST)
Number of subjects: 191
Study 36705965 — intervention group
Group type: EXPERIMENTAL
Intervention: GlobalConsent
Number of subjects: 793
Study 36705965 — intervention group
Group type: COMPARATOR
Intervention: AHEAD (attention-control)
Number of subjects: 793
Study 36706123 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibersol-2
Number of subjects: 92
Study 36706322 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 36706355 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine and ipilimumab
Number of subjects: 48
Study 36706355 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab
Number of subjects: 48
Study 36706355 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab monotherapy
Number of subjects: 48
Study 36706362 — intervention group
Group type: EXPERIMENTAL
Intervention: iTHRIVE 365
Number of subjects: 32
Study 36706364 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir, lamivudine/emtricitabine, and dolutegravir (TLD)
Number of subjects: 62
Study 36706364 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced adherence counseling
Number of subjects: 62
Study 36706435 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Insurance Education Program
Number of subjects: 0
Study 36706645 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib 200 mg twice daily during NACT
Number of subjects: 188
Study 36706645 — intervention group
Group type: COMPARATOR
Intervention: Placebo during NACT
Number of subjects: 188
Study 36706655 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib (300 mg/day fixed starting dose or individualized starting dose according to baseline body weight and platelet count)
Number of subjects: 316
Study 36706655 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized starting dose (ISD) of niraparib
Number of subjects: 316
Study 36706655 — intervention group
Group type: COMPARATOR
Intervention: Fixed starting dose of niraparib
Number of subjects: 316
Study 36706658 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative baseline EEG recordings (focused wakefulness and relaxed wakefulness)
Number of subjects: 89
Study 36706658 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline EEG recordings during relaxed and focused wakefulness
Number of subjects: 89
Study 36706675 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person counselling (45-70 minutes, two sessions over three months) with interim monthly booster phone calls (live call arm)
Number of subjects: 269
Study 36706675 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person counselling (45-70 minutes, two sessions over three months) with twice-weekly automated booster sessions (technology arm)
Number of subjects: 269
Study 36706675 — intervention group
Group type: COMPARATOR
Intervention: Live call arm
Number of subjects: 269
Study 36706675 — intervention group
Group type: COMPARATOR
Intervention: Technology arm
Number of subjects: 269
Study 36706754 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentivirus-based gene therapy
Number of subjects: 4
Study 36706754 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted treatments to protect HSCs
Number of subjects: 4
Study 36706778 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorfenapyr-pyrethroid LLINs
Number of subjects: 216289
Study 36706778 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyriproxyfen-pyrethroid LLINs
Number of subjects: 216289
Study 36706778 — intervention group
Group type: COMPARATOR
Intervention: Pyrethroid-only LLINs (reference group)
Number of subjects: 216289
Study 36706959 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoprogression (PSP)
Number of subjects: 180
Study 36706959 — intervention group
Group type: COMPARATOR
Intervention: True progression (TP)
Number of subjects: 180
Study 36706959 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor volume (TV) at relapse
Number of subjects: 180
Study 36706958 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-escalated radiotherapy to the whole primary tumour
Number of subjects: 150
Study 36706958 — intervention group
Group type: COMPARATOR
Intervention: Dose-escalated radiotherapy to a PET-defined subvolume
Number of subjects: 150
Study 36707080 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive antiplatelet therapy (combined clopidogrel and aspirin for days 1-21, then aspirin placebo and clopidogrel for days 22-90) plus immediate intensive statin therapy (atorvastatin at a dose of 80 mg daily for the first 21 days, then 40 mg daily for days 22-90)
Number of subjects: 6100
Study 36707080 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive antiplatelet therapy (combined clopidogrel and aspirin for days 1-21, then aspirin placebo and clopidogrel for days 22-90) plus delayed intensive statin therapy (atorvastatin placebo for days 1-3, followed by 40 mg per day of atorvastatin for days 4-90)
Number of subjects: 6100
Study 36707080 — intervention group
Group type: COMPARATOR
Intervention: Standard antiplatelet therapy (combination of clopidogrel placebo with aspirin for 90 days) plus immediate intensive statin therapy (atorvastatin at a dose of 80 mg daily for the first 21 days, then 40 mg daily for days 22-90)
Number of subjects: 6100
Study 36707080 — intervention group
Group type: COMPARATOR
Intervention: Standard antiplatelet therapy plus delayed intensive statin therapy
Number of subjects: 6100
Study 36707080 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 6100
Study 36707111 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic inspiratory muscle training (IMT) at 30% of maximal inspiratory pressure
Number of subjects: 36
Study 36707111 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic inspiratory muscle training (IMT) at 50% of maximal inspiratory pressure
Number of subjects: 36
Study 36707111 — intervention group
Group type: COMPARATOR
Intervention: Sham intradialytic inspiratory muscle training (sham-IMT) at 10% of maximal inspiratory pressure
Number of subjects: 36
Study 36707127 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced DLCO in current smokers
Number of subjects: 405
Study 36707127 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced DLCO in former smokers
Number of subjects: 405
Study 36707127 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced DLCO in never smokers
Number of subjects: 405
Study 36707127 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical implications of reduced DLCO
Number of subjects: 405
Study 36707127 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for low DLCO
Number of subjects: 405
Study 36707127 — intervention group
Group type: EXPERIMENTAL
Intervention: CT findings in smokers with reduced DLCO
Number of subjects: 405
Study 36707482 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy followed by robot-assisted minimally invasive esophagectomy (RAMIE) with three-field lymphadenectomy
Number of subjects: 29
Study 36707482 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy
Number of subjects: 29
Study 36707482 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted minimally invasive esophagectomy (RAMIE)
Number of subjects: 29
Study 36707489 — intervention group
Group type: EXPERIMENTAL
Intervention: Chan-Chuang qigong with breathing meditation
Number of subjects: 30
Study 36707489 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 30
Study 36707656 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully liquid presentation of MenACWY-CRM
Number of subjects: 0
Study 36707656 — intervention group
Group type: COMPARATOR
Intervention: Licensed presentation of MenACWY-CRM
Number of subjects: 0
Study 36707675 — intervention group
Group type: EXPERIMENTAL
Intervention: Students
Number of subjects: 0
Study 36707675 — intervention group
Group type: COMPARATOR
Intervention: Non-students
Number of subjects: 0
Study 36707764 — intervention group
Group type: EXPERIMENTAL
Intervention: MRE diet for 21 days
Number of subjects: 0
Study 36707764 — intervention group
Group type: COMPARATOR
Intervention: Habitual diet (HAB)
Number of subjects: 0
Study 36707778 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing PrEP (iPrEP)
Number of subjects: 40
Study 36707778 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 40
Study 36707808 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil (FTD/TPI) 35 mg/m²
Number of subjects: 914
Study 36707841 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of 20% hypertonic saline solution (HSS) to maintain blood sodium level between 150 and 155 mmol/L for at least 48 hours.
Number of subjects: 322
Study 36707841 — intervention group
Group type: COMPARATOR
Intervention: Standard of care as recommended by the latest Brain Trauma foundation guidelines.
Number of subjects: 322
Study 36707852 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineal wound infection
Number of subjects: 73
Study 36707852 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact anal sphincter
Number of subjects: 73
Study 36707852 — intervention group
Group type: EXPERIMENTAL
Intervention: OASIS
Number of subjects: 73
Study 36707909 — intervention group
Group type: EXPERIMENTAL
Intervention: Linkage navigation plus clinician referral
Number of subjects: 280
Study 36707909 — intervention group
Group type: COMPARATOR
Intervention: Clinician referral alone
Number of subjects: 280
Study 36708012 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with obesity
Number of subjects: 42
Study 36708012 — intervention group
Group type: COMPARATOR
Intervention: Women without obesity
Number of subjects: 42
Study 36708187 — intervention group
Group type: EXPERIMENTAL
Intervention: SPIN-CHAT Program
Number of subjects: 30
Study 36708371 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 6
Study 36708371 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (wild-type cases)
Number of subjects: 6
Study 36708371 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (FOXL2 mutation cases)
Number of subjects: 6
Study 36708381 — intervention group
Group type: EXPERIMENTAL
Intervention: Balneotherapy by immersion in 42℃ thermal-mineral water
Number of subjects: 137
Study 36708381 — intervention group
Group type: COMPARATOR
Intervention: Regular outpatient care
Number of subjects: 137
Study 36708469 — intervention group
Group type: EXPERIMENTAL
Intervention: ixazomib-dexamethasone
Number of subjects: 168
Study 36708469 — intervention group
Group type: COMPARATOR
Intervention: physician's choice
Number of subjects: 168
Study 36708539 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blockers (CCBs)
Number of subjects: 392
Study 36708539 — intervention group
Group type: COMPARATOR
Intervention: Non-CCB users
Number of subjects: 392
Study 36708539 — intervention group
Group type: EXPERIMENTAL
Intervention: CCB use
Number of subjects: 392
Study 36708539 — intervention group
Group type: EXPERIMENTAL
Intervention: CCB use in single antihypertensive agent
Number of subjects: 392
Study 36708539 — intervention group
Group type: EXPERIMENTAL
Intervention: CCB use in > 1 antihypertensive agent
Number of subjects: 392
Study 36708539 — intervention group
Group type: EXPERIMENTAL
Intervention: CCB use in controlled hypertension
Number of subjects: 392
Study 36708608 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support
Number of subjects: 0
Study 36708608 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomedical, relational, and socio-political models of peer support
Number of subjects: 0
Study 36708650 — intervention group
Group type: EXPERIMENTAL
Intervention: Propolis (4 capsules of 100 mg/day for two months)
Number of subjects: 41
Study 36708650 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 capsules of 100 mg/day for two months)
Number of subjects: 41
Study 36708691 — intervention group
Group type: EXPERIMENTAL
Intervention: Bova score
Number of subjects: 848
Study 36708691 — intervention group
Group type: EXPERIMENTAL
Intervention: ESC model
Number of subjects: 848
Study 36708691 — intervention group
Group type: EXPERIMENTAL
Intervention: PEITHO-3 model
Number of subjects: 848
Study 36708691 — intervention group
Group type: EXPERIMENTAL
Intervention: modified FAST score
Number of subjects: 848
Study 36708691 — intervention group
Group type: EXPERIMENTAL
Intervention: CT RV enlargement
Number of subjects: 848
Study 36708732 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose protein (≥2·2 g/kg per day)
Number of subjects: 1301
Study 36708732 — intervention group
Group type: COMPARATOR
Intervention: Usual dose protein (≤1·2 g/kg per day)
Number of subjects: 1301
Study 36708734 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate treatment over 2 years
Number of subjects: 240
Study 36708734 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment over 2 years
Number of subjects: 240
Study 36708738 — intervention group
Group type: EXPERIMENTAL
Intervention: CIS43LS 1 mg/kg intravenously
Number of subjects: 31
Study 36708738 — intervention group
Group type: EXPERIMENTAL
Intervention: CIS43LS 5 mg/kg intravenously
Number of subjects: 31
Study 36708738 — intervention group
Group type: EXPERIMENTAL
Intervention: CIS43LS 10 mg/kg intravenously
Number of subjects: 31
Study 36708738 — intervention group
Group type: EXPERIMENTAL
Intervention: CIS43LS 5 mg/kg subcutaneously
Number of subjects: 31
Study 36708738 — intervention group
Group type: EXPERIMENTAL
Intervention: CIS43LS 10 mg/kg subcutaneously
Number of subjects: 31
Study 36708738 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CIS43LS)
Number of subjects: 31
Study 36708911 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenient postoperative activity instructions
Number of subjects: 1250
Study 36708911 — intervention group
Group type: COMPARATOR
Intervention: Strict postoperative activity instructions
Number of subjects: 1250
Study 36708956 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine 20 mg/day
Number of subjects: 842
Study 36708956 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine 10-20 mg/day
Number of subjects: 842
Study 36708956 — intervention group
Group type: COMPARATOR
Intervention: Vortioxetine 5-20 mg/day
Number of subjects: 842
Study 36708956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 842
Study 36708956 — intervention group
Group type: COMPARATOR
Intervention: Agomelatine 25-50 mg/day
Number of subjects: 842
Study 36708966 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia tablet
Number of subjects: 59
Study 36708966 — intervention group
Group type: COMPARATOR
Intervention: Paper handout
Number of subjects: 59
Study 36709053 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung health check invitation
Number of subjects: 95397
Study 36709053 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-invitation of non-responders
Number of subjects: 95397
Study 36709053 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall uptake
Number of subjects: 95397
Study 36709053 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group comparison
Number of subjects: 95397
Study 36709053 — intervention group
Group type: EXPERIMENTAL
Intervention: Deprivation comparison
Number of subjects: 95397
Study 36709053 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethnicity comparison
Number of subjects: 95397
Study 36709053 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking status comparison
Number of subjects: 95397
Study 36709053 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethnicity subgroup analysis
Number of subjects: 95397
Study 36709074 — intervention group
Group type: EXPERIMENTAL
Intervention: cAd3-Marburg vaccine (1×10^11 viral particles)
Number of subjects: 40
Study 36709073 — intervention group
Group type: EXPERIMENTAL
Intervention: Momelotinib (200 mg orally once per day)
Number of subjects: 195
Study 36709073 — intervention group
Group type: COMPARATOR
Intervention: Danazol (300 mg orally twice per day)
Number of subjects: 195
Study 36709073 — intervention group
Group type: EXPERIMENTAL
Intervention: Momelotinib
Number of subjects: 195
Study 36709073 — intervention group
Group type: COMPARATOR
Intervention: Danazol
Number of subjects: 195
Study 36709271 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative sedation
Number of subjects: 0
Study 36709275 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 425809 2 mg
Number of subjects: 610
Study 36709275 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 425809 5 mg
Number of subjects: 610
Study 36709275 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 425809 10 mg
Number of subjects: 610
Study 36709275 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 425809 25 mg
Number of subjects: 610
Study 36709275 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 610
Study 36709275 — intervention group
Group type: EXPERIMENTAL
Intervention: All BI 425809 treatment groups
Number of subjects: 610
Study 36709386 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer remission group
Number of subjects: 477
Study 36709386 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 477
Study 36709533 — intervention group
Group type: EXPERIMENTAL
Intervention: Agalsidase beta treatment
Number of subjects: 176
Study 36709563 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitional Care Model (TCM)
Number of subjects: 0
Study 36709563 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative and quantitative data collection
Number of subjects: 0
Study 36709563 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategies implemented to address challenges
Number of subjects: 0
Study 36709563 — intervention group
Group type: EXPERIMENTAL
Intervention: General linear and mixed effects modeling
Number of subjects: 0
Study 36709637 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention (3×60 min sessions per week at 60 to 80% peak heart rate for 16 weeks)
Number of subjects: 135
Study 36709637 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aerobic exercise)
Number of subjects: 135
Study 36710105 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic Nutritional Index (PNI) ≤38
Number of subjects: 1371
Study 36710105 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlling Nutritional Status (CONUT) score >4
Number of subjects: 1371
Study 36710105 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric Nutritional Risk Index (GNRI) ≤91
Number of subjects: 1371
Study 36710105 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglycerides, Total Cholesterol, and Body Weight Index (TCBI) ≤1109
Number of subjects: 1371
Study 36710203 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Therapy
Number of subjects: 0
Study 36710203 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 36710205 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term androgen deprivation therapy (ADT)
Number of subjects: 1945
Study 36710205 — intervention group
Group type: COMPARATOR
Intervention: Standard criteria and omega score
Number of subjects: 1945
Study 36710243 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous abatacept
Number of subjects: 219
Study 36710319 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-To-Home NeuroPsychology (DTH-NP) via phone call and videoconference
Number of subjects: 58
Study 36710319 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face neuropsychological assessment
Number of subjects: 58
Study 36710346 — intervention group
Group type: EXPERIMENTAL
Intervention: CT imaging
Number of subjects: 434
Study 36710346 — intervention group
Group type: EXPERIMENTAL
Intervention: MR imaging
Number of subjects: 434
Study 36710399 — intervention group
Group type: EXPERIMENTAL
Intervention: roxadustat 2.0 mg/kg
Number of subjects: 92
Study 36710399 — intervention group
Group type: EXPERIMENTAL
Intervention: roxadustat 2.5 mg/kg
Number of subjects: 92
Study 36710399 — intervention group
Group type: EXPERIMENTAL
Intervention: roxadustat
Number of subjects: 92
Study 36710452 — intervention group
Group type: EXPERIMENTAL
Intervention: IDegLira
Number of subjects: 0
Study 36710452 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine U100
Number of subjects: 0
Study 36710828 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents of people diagnosed with BPD
Number of subjects: 106
Study 36710828 — intervention group
Group type: COMPARATOR
Intervention: Parents of people without a relative with a personality disorder
Number of subjects: 106
Study 36710894 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote, digitally supported consumer-electronics-based screening
Number of subjects: 100
Study 36711070 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermocosmetic (DC) applied twice daily for 28 days
Number of subjects: 41
Study 36711070 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermocosmetic (DC)
Number of subjects: 41
Study 36711127 — intervention group
Group type: EXPERIMENTAL
Intervention: Evoked potentials (EPs) at 3 ms (P3)
Number of subjects: 10
Study 36711127 — intervention group
Group type: EXPERIMENTAL
Intervention: Evoked potentials (EPs) at 10 ms (P10)
Number of subjects: 10
Study 36711127 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of EPs (P3 and P10) and image-derived information
Number of subjects: 10
Study 36711127 — intervention group
Group type: EXPERIMENTAL
Intervention: Image-derived information
Number of subjects: 10
Study 36711157 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning UNet model predicting non-perfused volume (NPV) without MRI contrast agents
Number of subjects: 95
Study 36711157 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning UNet model predicting NPV
Number of subjects: 95
Study 36711188 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Intensive-Upper Limb intervention (EI-UL)
Number of subjects: 16
Study 36711188 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Intensive-Upper Limb intervention with integrated Multisensory Stimulation And Priming (MuSSAP) training
Number of subjects: 16
Study 36711615 — intervention group
Group type: EXPERIMENTAL
Intervention: TAG72-CAR T cells
Number of subjects: 0
Study 36711615 — intervention group
Group type: EXPERIMENTAL
Intervention: mbIL12 CAR T cells
Number of subjects: 0